Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 outperforming placebo throughout the study (final assessment at Week 7). Durable improvements observed across abdominal pain, bowel habit parameters and IBS-specific quality of life, with benefit demonstrated in both constipation and diarrhoea-predominant IBS. EBX-102-02 was well tolerated, with no serious drug-related adverse events reported.

Today EBX announced positive results from its Phase 1b clinical trial evaluating EBX-102, the Company’s next-generation oral full-spectrum microbiome product, in patients with liver cirrhosis.

EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients. Ph2b trial in IBS-C initiating in H2 2025 to confirm efficacy

Today we announced that results from our IMPuLCE Phase 1b trial evaluating EBX-102, the Company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025.

Today we announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be held 3–6 May in San Diego, USA.

EnteroBiotix Limited, a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced positive initial results with EBX-102-02, the Company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase 2a clinical trial in adults with irritable bowel syndrome with constipation (IBS-C).

122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase 2 TrIuMPH trial assessing EBX-102-02. EnteroBiotix completed enrolment ahead of its planned schedule, dosing 62 participants with constipation predominant IBS and 60 participants with diarrhoea predominant IBS

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy for individuals with liver disease

EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

EnteroBiotix announced that the first patient has been dosed in a multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of IBS.

EnteroBiotix, a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its Board of Elmar Schnee as Executive Chairman.

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

EnteroBiotix partners with Imperial College London to advance microbiome therapeutics

EnteroBiotix today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials. The facility also incorporates an in-house QC hub and analytical department.

EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the Board appointment of David Lawrence as an independent Non-Executive Director.

EnteroBiotix is pleased to announce that the Company has received full registration of their trademark “Number 2”. The Number 2 brand forms a core part of the Company’s strategy to control the supply chain for its Broad Spectrum Microbiota™ therapeutics.

Watch an interview with our Founder and CEO Dr. James McIlroy, where he shares our vision for mastering the microbiome to transform lives of patients.